Free Trial

Lantheus (LNTH) Stock Price, News & Analysis

Lantheus logo
$57.20 +2.34 (+4.27%)
Closing price 04:00 PM Eastern
Extended Trading
$56.55 -0.65 (-1.14%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lantheus Stock (NASDAQ:LNTH)

Key Stats

Today's Range
$53.69
$57.21
50-Day Range
$51.87
$83.83
52-Week Range
$47.25
$118.21
Volume
2.50 million shs
Average Volume
1.88 million shs
Market Capitalization
$3.89 billion
P/E Ratio
10.09
Dividend Yield
N/A
Price Target
$114.50
Consensus Rating
Moderate Buy

Company Overview

Lantheus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

LNTH MarketRank™: 

Lantheus scored higher than 92% of companies evaluated by MarketBeat, and ranked 88th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Lantheus has only been the subject of 4 research reports in the past 90 days.

  • Read more about Lantheus' stock forecast and price target.
  • Earnings Growth

    Earnings for Lantheus are expected to grow by 4.99% in the coming year, from $6.01 to $6.31 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lantheus is 15.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.93.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lantheus is 15.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.11.

  • Price to Book Value per Share Ratio

    Lantheus has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    12.25% of the float of Lantheus has been sold short.
  • Short Interest Ratio / Days to Cover

    Lantheus has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Lantheus has recently decreased by 5.40%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lantheus does not currently pay a dividend.

  • Dividend Growth

    Lantheus does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.25% of the float of Lantheus has been sold short.
  • Short Interest Ratio / Days to Cover

    Lantheus has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Lantheus has recently decreased by 5.40%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Lantheus has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 37 news articles for Lantheus this week, compared to 11 articles on an average week.
  • Search Interest

    18 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 260% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,002,651.00 in company stock.

  • Percentage Held by Insiders

    Only 1.50% of the stock of Lantheus is held by insiders.

  • Percentage Held by Institutions

    99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lantheus' insider trading history.
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

LNTH Stock News Headlines

GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.
Lantheus (LNTH) Q2 Revenue Falls 4%
Why Lantheus (LNTH) Stock Is Falling Today
See More Headlines

LNTH Stock Analysis - Frequently Asked Questions

Lantheus' stock was trading at $89.46 at the start of the year. Since then, LNTH shares have decreased by 36.1% and is now trading at $57.20.

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings data on Wednesday, August, 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by $0.08. The firm's quarterly revenue was down 4.1% on a year-over-year basis.
Read the conference call transcript
.

Lantheus (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Lantheus' top institutional shareholders include Geode Capital Management LLC (2.57%), Reinhart Partners LLC. (2.03%), TD Asset Management Inc (0.91%) and Boston Partners (0.83%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Etienne Montagut, Andrea Sabens, James H Thrall, Heinz Christoph Maeusli, Gerard Ber, Brian A Markison, Gary J Pruden and Minnie Baylor-Henry.
View institutional ownership trends
.

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
8/06/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LNTH
CIK
1521036
Employees
700
Year Founded
N/A

Price Target and Rating

High Price Target
$175.00
Low Price Target
$70.00
Potential Upside/Downside
+104.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.52
Trailing P/E Ratio
14.83
Forward P/E Ratio
9.30
P/E Growth
N/A
Net Income
$312.44 million
Net Margins
17.82%
Pretax Margin
24.75%
Return on Equity
34.06%
Return on Assets
19.10%

Debt

Debt-to-Equity Ratio
0.49
Current Ratio
4.29
Quick Ratio
5.46

Sales & Book Value

Annual Sales
$1.53 billion
Price / Sales
2.52
Cash Flow
$7.65 per share
Price / Cash Flow
7.31
Book Value
$16.86 per share
Price / Book
3.32

Miscellaneous

Outstanding Shares
69,190,000
Free Float
68,148,000
Market Cap
$3.87 billion
Optionable
Optionable
Beta
0.14
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:LNTH) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners